F2G’s Olorofim Receives the US FDA’s Breakthrough Therapy Designation to Treat Invasive Mold Infections in Patients with Limited or No Treatment Options

 F2G’s Olorofim Receives the US FDA’s Breakthrough Therapy Designation to Treat Invasive Mold Infections in Patients with Limited or No Treatment Options

Shots:

  • The BT designation follows the P-IIb Trial in patients with IFD or probable invasive aspergillosis (IA) and either refractory disease, resistance, or intolerance to available agents
  • The study resulted in well tolerable results across more than 10 years of patient dosing days with a median therapy duration of 12 wks.
  • Olorofim is first antifungal agent targeted to treat invasive fungal mold infections such as azole-resistant aspergillosis, scedosporiosis, lomentosporiosis, and other rare mold infections and is being developed as IV and oral formulation

Click here ­to­ read full press release/ article | Ref: PRNewswire  | Image: F2G

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post